On April 2, 2024 Domain Therapeutics ("Domain" or "the Company"), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), reported its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024 (Press release, Domain Therapeutics, APR 2, 2024, View Source [SID1234641692]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bloom Burton & Co. Healthcare Investor Conference – April 16-17
Location: Metro Toronto Convention Centre (North Building), Toronto, Canada
Presentation slot: Wednesday, April 17, 3:30 PM ET, Room 104 A
LSX World Congress – April 29-30
Location: Business Design Centre, London, UK
Bio€quity Europe – May 12-14
Location: Kursaal Elkargunea Center, San Sebastián, Spain
Presentation slot: to be announced at a later date
The portfolio currently boasts the following novel drug candidates in the rapidly evolving cancer field of resistance in the tumor micro-environment:
DT-7012, a best-in-class Treg-depleting anti-CCR8 monoclonal antibody
DT-9045, a first-in-class, PAR2 biased ligand Negative Allosteric Modulator, small molecule
DT-9081, an EP4R antagonist program, small molecule currently in Phase I ascending dose study